PTC-596 in Women With Ovarian Cancer Receiving Neoadjuvant Chemotherapy
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This is an open-label Phase Ib dose-escalation study to determine the safety, tolerability,
and pharmacokinetics of PTC-596 when combined with and following conventional chemotherapy
and as maintenance therapy as a capsule (weight based dosing) and a tablet (fixed dosing) in
women with epithelial ovarian, fallopian tube or primary peritoneal cancer which is
previously untreated.